New drug combo tested to control rare blood cancer without chemotherapy
NCT ID NCT07355699
Summary
This study is testing a drug called orelabrutinib, given alone or with another antibody drug, to treat people newly diagnosed with marginal zone lymphoma, a type of blood cancer. It aims to see if this approach is effective and safe, potentially offering a treatment option that avoids traditional chemotherapy. The trial will enroll 88 adults and will monitor how well the cancer responds and how patients tolerate the treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA (MZL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Tongren Hospital
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Peking Union Medical College Hospital
NOT_YET_RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of China Medical University
NOT_YET_RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.